Skip to Content

DESTINY-Breast03 Study: Trastuzumab Deruxtecan versus Trastuzumab Emtansine

Let Giuseppe Curigliano from the European Institute of Oncology IRCCS present you patient-reported outcomes in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.

Giuseppe Curigliano

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top